Close Menu

NEW YORK (GenomeWeb) – Cancer molecular diagnostics firm Empire Genomics announced today that it has signed a distribution deal for its products in China with contract research organization HemaTone Beijing.

Growing demand in the region for cancer diagnostics was the impetus for the deal, which is expected to bring in more than $5 million in revenues for Empire over the five-year term of the agreement, the company said. HemaTone will distribute Empire's personalized diagnostic testing products in China, and will provide product training and marketing support to its clients.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.